Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of INCB123667 monotherapy in advanced solid tumors
NL-OMON53884Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB123667 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 10 more (7 arms), sponsored by Incyte. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
INCB123667
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)clear cell ovarian cancer
Beyond the preview
Go deeper on NL-OMON53884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53884.